First patient treated in dose expansion cohort of Targovax's ONCOS-102 trial in melanoma
·Trial extended in checkpoint inhibitor refractory melanoma with up to 12 additional patients receiving an increased dosing regimen of 12 ONCOS-102 injections and 8 cycles of Keytruda ·First patient in dose expansion cohort has received the first ONCOS-102 injection Oslo, Norway, 11 February 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that the first patient has received ONCOS-102 in the dose expansion cohort of the ongoing phase I trial in checkpoint inhibitor (CPI)